WuXi XDC

The biopharmaceutical industry is witnessing an exciting evolution with the emergence of bioconjugates that extend beyond the traditional antibody-drug conjugates (ADCs). As exploring new horizons in bioconjugate technology, how to address the unique challenges along the development of novel bioconjugates? what can we leverage the knowledge gained from ADCs to guide the development while circumventing the obstacles that have been encountered in the past? At a closed-door symposium during the Global XDC Innovation Conference, hosted by WuXi XDC, an esteemed panel of experts across the globe delved into the challenges, differences, and unique considerations in the development of next-generation bioconjugates, bringing insights for a strategic and efficient approach to advance bioconjugate development. Click on the image below to view the full insightful article. #conjugates #bioconjugates #ADCs #antibodydrugconjugate

The complexity of traditional and novel bioconjugates present significant challenges in the analytical development, including the need to assess linker-payload stability, conjugation heterogeneity (in terms of site and ratio), and process-related impurities, as well as to develop specialized assays to monitor the conjugation process. Moreover, a critical aspect is the efficient development of analytical methods tailored to the diversity of bioconjugates. During the upcoming webinar on Dec.5th, Dr. ZHIGUO LI, Executive Director, Head of Analytical Development and Characterization Team at WuXi XDC, will address the following key topics: 1. The critical quality attributes (CQAs) to monitor during process development 2. Case studies for various physicochemical and biochemical methods 3. Mass spectrometry application in PD support and product characterization 4. WuXi XDC’s integrated analytical platform for bioconjugate CMC development Register now for the webinar: https://lnkd.in/gqN8SRtw

Join our upcoming webinar in collaboration with BioPharm International for “Integrated Analytical Platform Accelerates CMC Bioconjugate Development”. Dr. ZHIGUO LI, Executive Director, Head of Analytical Development and Characterization Team at WuXi XDC, will delve into the development of physicochemical and biochemical analysis methods for various types of bioconjugates, and present an integrated analytical strategy to address development hurdles and accelerate the CMC timeline. ?? Key topics to be covered by Dr. Li's presentation: 1. The critical quality attributes (CQAs) to monitor during process development 2. Case studies for various physicochemical and biochemical methods 3. Mass spectrometry application in PD support and product characterization 4. WuXi XDC’s integrated analytical platform for bioconjugate CMC development Find more info and to register for this webinar: https://lnkd.in/gqN8SRtw ?

At WuXi XDC, we're dedicated to providing the bioanalysis expertise that can make a difference in your ADC development: ?? Extensive Cellular Models: We've established over 200 disease-specific cellular models, providing a robust foundation for studying ADC efficacy and safety profiles across a wide spectrum of diseases ??Proprietary Technologies: With more than 10 proprietary technologies, be able to uncover the efficacy and safety attributes of ADCs, offering insights that are crucial for drug development ?? Vast Therapeutic Target Molecules: We've worked with over 250 therapeutic target molecules, covering nearly all modes of action, well-equipped to support a wide array of bioanalysis needs ?? Engineered Cell Lines: More than 20 engineered cell lines expressing target molecules, which have been rigorously tested in bioassays for precise and reliable results ?? Assays for ADCs: With an impressive portfolio of over 100 ADC product-specific cell-based assays, more than 50 qualified in GMP conditions Connect to our experts to learn more: https://lnkd.in/eCgHTVqf

The development of antibody-drug conjugates (ADCs) involves complex, multifaceted efforts that includes the optimization of antibody, the selection of potent payloads, linkers technology and conjugation innovation. How to navigate the complexities within the ADCs/ Bioconjugates evolution? In a recent closed-door discussion at Global XDC Innovation Conference, hosted by WuXi XDC, a panel of experts from global wide Biopharma and Biotech companies delve into these topics, bringing inspired insights for next generation ADCs development. View the full insightful article here: #ADC #ADCs #antibodydrugconjugate #antibodydrugconjugates #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #GlobalXDC2024

Bioassays stand as the exclusive in vitro analytics capable of reflecting the clinical effect of products. They play a unique role in evaluating the therapeutic impact throughout the entire biologics’ development value chain. The Bioassay and Translational Medicine Center of Excellence at WuXi XDC is equipped to offer comprehensive services, including bioassay development, qualification, and sample analysis for all XDC modalities. We also support target selection, potency assessment, off-target effects, extended product and intermediate characterizations and CQA and TPP evaluations. Furthermore, we specialize in standalone bioanalytical services for PK, PD, biomarker, immunogenicity (neutralization) testing, toxicology, biosafety testing and analytical cell line development. Our proprietary technologies can reveal XDC efficacy & safety attributes otherwise invisible. We support 15-months ADCs/XDC product development from DNA to IND without any major observation from 45+ external and regulatory audits per year. Connect to our experts to learn more: https://lnkd.in/eCgHTVqf #bioanalysis #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugconjugate?

Our experts recently showcased an insightful scientific poster: “Mitigation of Challenges in Impurity Specification in Linker Payload”. In this poster, we discussed the specialized analytical methods that WuXi XDC has developed to assess the content and conjugatable characteristics of impurities. Our methodical approach involves verifying the conjugatable nature of impurities through mock-conjugation experiments and controlling homologue impurities in starting materials using advanced analytical techniques, thereby reducing their presence in the final linker-payload. Interested in this poster? Reach out to get a digital copy: https://lnkd.in/gQuJpFUf #WorldADCSanDiego #ADCs #conjugates #bioconjugate

Last week, at the World ADC San Diego conference, our experts showcased an insightful scientific poster： ?? Poster: Novel Conjugation and Payload-Linker Technologies for Next Generation ADCs This poster detailed how WuXi XDC has built a robust platform for the development of next-generation ADCs through a combination of internal development and external collaboration. Our approach is designed to tackle the complex challenges of bioconjugations. If you couldn’t make it to world ADC San Diego, you can request a digital copy of our poster here: https://lnkd.in/g92FVcM7 #WorldADCSanDiego #ADCs #Payloadlinker?#conjugates #bioconjugate

Needs premium yet affordable conjugation enzyme for ADC? ?WuXi XDC offers fully integrated development and manufacturing services for GMP-grade conjugation enzymes such as FTase, Sortase A, TTL, MTGase and Glycosyltransferase. Starting from our state-of-the-art microbial production system, we tailor your program to meet your specific timeline, cost, and quality requirements. (IPs related to the above-mentioned enzymes are not owned by WuXi XDC) Learn more at https://lnkd.in/eGiFJvY9. #enzyme #toolenzyme #conjugation #microbial #proteinintermediate #proteinproduction #biotherapeutics

We are proud to announce that WuXi XDC was named the winner of the “Best CDMO” ?at this year's World ADC in San Diego for the second consecutive year. Over the past three years, WuXi XDC has consistently earned recognitions at previous World ADC conferences in San Diego, including being named the winner of the “Best CDMO” in 2023 and “Best CMO Runner-up” in 2022. WuXi XDC was also shortlisted this year for “Best ADC Platform Technology” and “Best CRO”, highlighting its strong R&D capability and contributions to ADC development. The prestigious award, presented at this week's World ADC conference in San Diego, recognizes WuXi XDC end-to-end, one-stop CRDMO excellence and exceptional services to global clients. The company's record of consecutive awards highlights its expertise and technical strength in driving innovation in the global ADC industry and meeting the complex needs from clients worldwide. Big thanks to World ADC Event Series and all the judges of the awards! https://lnkd.in/g2hH7Cnj #WorldADCEventSeries #WorldADCAward #WorldADCSanDiego #ADC #Bioconjugate #CDMO